Samsung Biologics said it will participate in the 2025 J.P. Morgan Healthcare Conference (JPMHC), the world’s largest pharmaceutical and biotechnology investment conference.

Celebrating its 43rd year, the JPMHC will take place from Jan. 13 to 16 in San Francisco, California. This year, the event is expected to host more than 550 pharmaceutical, biotechnology, and healthcare companies, with over 8,000 participants attending.

Samsung Biologics, officially invited by J.P. Morgan for the ninth consecutive year since 2017, will deliver a presentation on the conference’s main stage, the Grand Ballroom. Only 27 companies, among the 550 invited, are selected to present in the Grand Ballroom, highlighting their significance within the industry.

Samsung Biologics will present on the second day of the conference, sharing the stage with multinational pharmaceutical companies, including GlaxoSmithKline (GSK), Eli Lilly, and AstraZeneca.

CEO John Rim will personally lead the presentation on Jan. 14 at 3:00 p.m. at The Westin St. Francis Hotel. The company stressed that Rim’s address, themed "4E (Excellence)," will detail the company's record-breaking achievements under his leadership, strategic plans for 2025, and its long-term vision for growth.

The 4E philosophy—Customer Excellence, Operational Excellence, Quality Excellence, and People Excellence—was introduced by Rim to underscore the core values that Samsung Biologics aims to uphold.

During the conference, Samsung Biologics plans to also engage in strategic meetings with investors and potential clients to showcase its differentiated capabilities as a global contract development and manufacturing organization (CDMO).